Skip to main content
Sanofi India Ltd logo

Sanofi India Ltd — Investor Relations & Filings

Ticker · SANOFI ISIN · INE058A01010 LEI · 335800VFWLEY5V6PYH80 BSE.NS Manufacturing
Open in API
Filings indexed 1,554 across all filing types
Latest filing 2023-04-11 Regulatory Filings
Country IN India
Listing BSE.NS SANOFI

About Sanofi India Ltd

https://www.sanofi.in

Sanofi India Ltd focuses on the development, manufacturing, and marketing of a wide range of pharmaceutical products and healthcare solutions. The company operates across several therapeutic areas, including diabetes, cardiology, thrombosis, central nervous system disorders, and consumer healthcare. Its product portfolio includes established brands such as Lantus, Allegra, Combiflam, Amaryl, Avil, and Enterogermina. The organization prioritizes chronic disease management and acute care through a combination of prescription medicines and over-the-counter treatments. By integrating global research capabilities with local manufacturing excellence, the company provides specialized medical solutions aimed at improving patient health outcomes and addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
Announcement under Regulation 30 - NLEM Communication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, which pertains to disclosure of material events. The content informs about a price ceiling imposed by the National Pharmaceutical Pricing Authority on a product, leading to a price reduction and expected impact on sales and profitability. The document is an intimation or announcement of a material event affecting the company, not a financial report or detailed analysis. The length is short (2324 characters), and it is a regulatory disclosure of a material event rather than a report or presentation. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback for such regulatory announcements that do not fit other categories.
2023-04-11 English
Updates
Regulatory Filings Classification · 95% confidence The document is a detailed communication from Sanofi India Limited regarding the deduction of tax at source (TDS) on dividends. It includes information about dividend payments recommended by the Board, tax deduction rules for resident and non-resident shareholders, and instructions for submitting tax-related forms (Form 15G, 15H, 10F). The document is addressed to shareholders and stock exchanges, and it primarily serves as a notification about tax withholding on dividends rather than announcing dividend amounts or payment dates explicitly. It is not a dividend declaration notice (which would focus on dividend amounts and payment schedules), nor is it a proxy solicitation, earnings release, or financial report. The document is regulatory in nature, providing compliance information and instructions related to tax deduction on dividends. It does not contain financial statements or management discussion. Given the content and purpose, the most appropriate classification is Regulatory Filings (RNS), as it is a regulatory announcement related to tax deduction on dividends but not a direct dividend notice or financial report.
2023-04-11 English
Please find enclosed copy of the letter for deduction of tax at source on Dividend sent to the shareholders today i.e., 11th April 2023 through email who have registered their email ID ....
Notice of Dividend Amount Classification · 95% confidence The document is a communication from Sanofi India Limited regarding the deduction of tax at source (TDS) on dividends. It includes detailed instructions and forms related to tax deduction for dividend payments for the financial year ended 31st December 2022. The document is addressed to shareholders and stock exchanges, explaining tax provisions, submission of forms, and compliance requirements. It does not contain financial statements, earnings data, or management discussion but is rather an official announcement about dividend tax deduction procedures and related shareholder communication. The document length is 15,000 characters, indicating it is a detailed communication but not a full financial report. This fits best under the category of Notice of Dividend Amount (DIV), as it relates to dividend payment details and tax deduction on dividends.
2023-04-11 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a letter dated 11th April 2023 from the company Sanofi India Limited addressed to stock exchanges. It announces a meeting of the Board of Directors scheduled for 10th May 2023 to consider the unaudited financial results for the quarter ended 31st March 2023. It also mentions the closure of the trading window for insiders during the period around the financial results publication. The document is an announcement about a future board meeting and financial results consideration, not the financial results report itself. It does not contain any financial data or detailed report content. The document is short (1822 characters) and serves as a notification to the stock exchanges and public about the board meeting and trading window closure. Therefore, it fits best under the category of Board/Management Information (MANG), as it relates to board meeting announcements and compliance with regulatory disclosure requirements about board activities.
2023-04-11 English
Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2023 ,inter alia, to consider and approve the Unaudited Financial Results ....
Board/Management Information Classification · 95% confidence The document is a letter from the company secretary informing stock exchanges about a scheduled Board of Directors meeting to consider unaudited financial results for the quarter ended 31st March 2023. It also mentions the closure of the trading window related to the publication of these financial results. The document is short (1822 characters) and serves as a notification of an upcoming board meeting and related compliance matters, not the financial results themselves or detailed management discussion. Therefore, it is best classified as a Board/Management Information (MANG) filing, which covers announcements about board meetings and related management information.
2023-04-11 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, provided by the Registrar and Share Transfer Agent (RTA) for the quarter ended 31st March 2023. It is a short communication addressed to stock exchanges requesting to take the certificate on record. There is no financial data, report content, or detailed analysis present. The document is primarily a regulatory compliance certificate, not a full financial report or announcement of financial results. It fits the criteria of a Regulatory Filing (RNS) as it is a compliance document and does not contain substantive financial or management information.
2023-04-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.